Article Sidebar
Published:
Jun 25, 2013DOI:
10.4314/tjpr.v12i3.2Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Preliminary Studies on Solid Lipid Microparticles of Loratadine for the Treatment of Allergic Reactions via the Nasal Route
Abstract
Purpose: To formulate solid lipid microparticles (SLM) of loratadine (LRT) for the treatment of allergic reactions via the nasal route.
Methods: Microparticles were prepared by emulsion congealing technique. The drug content of microparticles was analysed. Drug/excipient compatibility and crystallinity characteristics of microparticles were investigated by Fourier Transform Infrared Spectroscopy (FT-IR) and differential scanning calorimetry (DSC). Particle size distribution was determined by laser diffraction (LD). Drug release from microparticles was compared to that from conventional vehicles (O/W emulsion, gel and
oleageneous cream) using Franz-type diffusion cells.
Results: Drug content of microparticles was > 87.96 %. FT-IR and DSC analysis indicated that the drug and excipients were compatible for at least 6 months at room temperature after production. Microparticle size was between 86 ± 5.63 ìm and 184 ± 13.21 ìm while mean droplet size of O/W
emulsion was 76 ± 3.45 ìm. Release profiles of LRT from microparticles were significantly different from those of O/W emulsion, gel and oleageneous cream (p < 0.05). In the case of conventional vehicles,
increase in the hydrophilicity of the vehicles led to increase in drug release rate. Drug release fitted generally to zero order kinetics as well as Korsmeyer-Peppas model for one of the SLM formulations, indicating non-Fickian drug release (super case II transport).
Conclusion: SLM provided LRT release for a longer period than the conventional vehicles. However, in vivo studies are required to ascertain the effectiveness of the formulations.
Keywords: Loratadine, Solid lipid microparticles, Allergy, Controlled drug delivery, Transnasal delivery
